Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $10

Benzinga Newsdesk www.benzinga.com Negative 46.9%

Neg 46.9% Neu 0% Pos 0%

Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $22 to $10.